Biotech entrepreneur Saurabh Saha moves to translational research chief at Bristol-Myers; Ex-GSK pharma chief Hussain switches to private equity
→ Bristol-Myers Squibb $BMY has hired Saurabh Saha to run their translation science group, which is responsible for triaging preclinical work of interest and steering the most promising programs toward the clinic. Saha — a 40-year-old Johns Hopkins grad, where he worked in Bert Vogelstein’s lab — once upon a time labored inside Novartis’ global ops, before leaving for a string of new jobs in biotech. Nine years ago he set up a translational research and development organization called BioMed Valley Discoveries. Then his role as a venture partner at the prolific Atlas Venture led him to become chief medical officer at Synlogic, followed by a brief but wildly successful stint as CEO of Delinia. Saha is staying in the Boston area, where Bristol-Myers is building a new R&D center.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
